The trading price of Novo Nordisk ADR (NYSE:NVO) floating higher at last check on Tuesday, April 23, closing at $128.24, 2.38% higher than its previous close.
The company’s P/E ratio in the trailing 12-month period was 47.47. In examining the 52-week price action we see that the stock hit a 52-week high of $138.28 and a 52-week low of $75.56. Over the past month, the stock has lost -0.41% in value.
Novo Nordisk ADR, whose market valuation is $433.87 billion at the time of this writing. The dividend yield on the company stock is 1.07%, while its Forward Dividend ratio is 1.37. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $0.73 per share this quarter, however they have predicted annual earnings per share of $3.34 for 2024 and $4.01 for 2025. It means analysts are expecting annual earnings per share growth of 25.60% this year and 20.10% next year.
Analysts have forecast the company to bring in revenue of $8.98 billion for the current quarter, with the likely lows of $8.65 billion and highs of $9.37 billion. The average estimate suggests sales will likely up by 18.40% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2024 is $41.14 billion. The company’s revenue is forecast to grow by 24.20% over what it did in 2024.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Novo Nordisk ADR no upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest NVO has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 16.95, which symbolizes a positive outlook. A quick review shows that NVO’s price is currently 1.96% off the SMA20 and 1.54% off the SMA50. The RSI metric on the 14-day chart is currently showing 56.75, and weekly volatility stands at 1.92%. When measured over the past 30 days, the indicator reaches 1.75%. Novo Nordisk ADR (NYSE:NVO)’s beta value is currently sitting at 0.44, while the Average True Range indicator is currently displaying 2.64.
To see how Novo Nordisk ADR stock has been performing today in comparison to its peers in the industry, here are the numbers: NVO stock’s performance was 2.38% at last check in today’s session, and 48.55% in the past year. Novo Nordisk ADR has a P/E ratio of 47.47.
An evaluation of the daily trading volume of Novo Nordisk ADR (NYSE:NVO) indicates that the 3-month average is 5.07 million.
Currently, records show that 3.38 billion of the company’s shares remain outstanding. The insiders hold 0.00% of outstanding shares, whereas institutions hold 9.19%. However, since the stock’s price has seen 23.96% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
